Health Science

Alzheimer's Drugs Benefits Questioned

Alzheimer's Drugs Benefits Questioned

The review of 17 clinical trials involving anti-amyloid drugs found that while the medicines successfully remove plaques from the brain, they fail to significantly slow cognitive decline.

Researchers described the clinical benefits as 'trivial' and highlighted the serious risks of brain swelling and bleeding associated with the treatments.

Some dementia experts have criticized the analysis, arguing that it unfairly groups failed experimental drugs with recently approved breakthroughs.

The report's conclusions could have profound implications for how healthcare systems like the NHS prioritize funding for expensive new Alzheimer's therapies.